OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 87. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma	1681
Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche	1607
Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry	907
First Line B+R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real-World Experience	476
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cel	283
Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance	235
Association of Thrombospondin-1 Gene Polymorphism with Elevated Tricuspid Regurgitant Velocity in Sickle Cell Anemia	219
Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine	200
Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review	192
Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Dis	185
Effects of Bypassing Hemostatic Agents in the Co-Presence of NXT007, Emicizumab-Based Engineered Bispecific Antibody to Fixa/Fx, Using in Vitro Global Assays: Rough Indicators for Their Concomitant Us	182
Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies	169
Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles	160
Platelets are hot and cold, RhoA is up and down	159
TPO-RAs and ITP remission: cause or coincidence?	158
ERG: the good, the bad, and the ugly	151
An AID to follicular lymphoma transformation	150
Unexpected parvovirus B19 infection in a patient with multiple myeloma	145
Aging-disturbed FUS phase transition impairs hematopoietic stem cells by altering chromatin structure	142
Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance	141
Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100	140
Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells	138
The Impact of Revised Definitions for TACO and TRALI on Hemovigilance Reporting	135
Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL	133
Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States	132

Clinical, Cytogenetic, and Molecular Characteristics Analysis in Myelodysplastic Syndromes with Elevated Ferritin Levels	131
Simultaneous occurrence of KSHV-associated malignancies in a patient affected by HIV	130
Bleeding tendency with corkscrew hair	130
PI3king apart a rare disease with targeted therapy	129
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy	128
Proton export takes charge of proliferation	128
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria	128
Breaking T-cell tolerance in the immune system	125
Single-cell genomics in acquired bone marrow failure syndromes	124
Targeting PKCα decreases iron overload in diabetes	122
Epigenetic deregulation in myeloid malignancies	120
Heparin or nonheparin anticoagulants for VITT	119
GADD45A: a key tumor suppressor in AML subtypes	118
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies	117
CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication	116
Baby steps in managing CVAD-related thrombosis	115
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma	111
Pseudo-Gaucher cells in a myeloid neoplasm with PDGFRB rearrangement: imitating the imitator	110
Heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice	110
One step at a time	110
An ATLAS to map MRD with peripheral blood	109
Selecting CD7− T cells for CAR T-cell therapy	109
Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles	108
Contactless edema via plasmin	108
MDM2 inhibition augments GVL effect	107
Blast phagocytosis	107
Waking up exhausted BCMA-specific T cells in myeloma	107
Poverty and health equity in childhood leukemia	107
Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia	107
High-mobility-group protein A1 in MPN progression	106
Increasing microenvironment complexity in HL	106
Renewing your HBO1 subscription	105
Role and timing of chromosome deletions in multiple myeloma	104
Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association	103
Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia	102
Towards a standard of care in transplant for WAS	102
Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older	101
How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?	101
How I manage pregnant patients who are alloimmunized to RBC antigens	101
Combined Plasma Fibrinogen and Neutrophil-Lymphocyte Ratio As a Predictive Factor in Patients with Diffuse Large B-Cell Lymphoma	100
Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib	100
Development and Validation of a Novel Prognostic Nomogram Model and a Web-Based Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era	100
CSF3R Splicing Regulates Granulopoiesis Via Splice Variant Specific Responses to G-CSF	100
CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK	99
Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant	97
Manipulating MEF2C: Discovering Novel Drugs to Target ETP-ALL	97
Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study	97
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	94
Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hem	93
Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia	92

Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy	91
Validating Direct Oral Anticoagulants (DOAC) for Use in Children By the Throm-PED Doac Registry of the International Pediatric Thrombosis Network	91
Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia	91
Herpesvirus Infections of Intestinal Tract in the Patients with Intestinal Graft-Versus-Host Diseases: Laboratory Diagnosis Based on DNA Detection By Real-Time Quantitative PCR in Feces Samples	90
Antiaging for Ph-like ALL: targeting senescence	90
Erythropoiesis Stimulating Agents (ESAS) in Supportive Care of Low-Risk Myelodysplastic Syndromes: Recamds Registry FINAL Results	89
The chromatin accessibility landscape of pediatric AML	89
The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms' Tumor 1 Peptide Vaccination	89
Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients	88
Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United	88
Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease	88
Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study	87